Population pharmacokinetics of artesunate and amodiaquine in African children

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Stepniewska, Kasia ^a,b   Taylor, Walter ^a,b,c   Sirima, Sodiomon B ^d,e   Ouedraogo, Esperance B ^d   Ouedraogo, Alphonse ^d   Gansané, Adama ^d   Simpson, Julie A ^f   Morgan, Caroline C ^g   White, Nicholas J ^a,b   Kiechel, Jean René ^h  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Burkina Faso   (Burkina Faso)

^e Groupe de Recherche Action en Sante   (Burkina Faso)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Cardinal Systems   (France)

^h Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARSUCAM; ARTESUNATE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; PARACETAMOL; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE AMODIAQUINE COMBINATION; ARTESUNATE-AMODIAQUINE COMBINATION;

ABDOMINAL PAIN; ACUTE DISEASE; AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOCRIT; HUMAN; INFANT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALARIA; MALE; NAUSEA; NEUTROPENIA; POLYMERASE CHAIN REACTION; POPULATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; THROMBOCYTE COUNT; VERTIGO; VOMITING; WEAKNESS; BIOAVAILABILITY; BIOTRANSFORMATION; CHEMISTRY; DRUG COMBINATION; PLASMA; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

AFRICA; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; MALARIA; MALE; PLASMA; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349085389     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-200     Document Type: Article

References (23)

1. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. RW Snow M Craig U Deichmann K Marsh, Bull World Health Organ 1999 77 624 640 10516785
2. Guidelines for the treatment of malaria. World Health Organization, 2006 http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
3. How do patients use antimalarial drugs? A review of the evidence. S Yeung NJ White, Trop Med Int Health 2005 10 121 138 10.1111/j.1365-3156.2004.01364.x 15679555
4. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. J Connor N Dafter A Rodgers, Bull World Health Organ 2004 82 935 939 15654408
5. The story of ASAQ: the first antimalarial product development partnership success. B Pecoul A Sevcsik J Amuasi G Diap J Kiechel, Health Partnerships Review 2008 http://www.actionforglobalhealth.eu/news/http-www-globalforumhealth- org-filesupld-hpr-healthpartnershipsreview-full-pdf
6. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. SB Sirima AB Tiono A Gansane A Diarra A Ouedraogo AT Konate JR Kiechel CC Morgan PL Olliaro WR Taylor, Malar J 2009 8 48 10.1186/1475-2875-8-48 19291301
7. A randomised, controlled, open-label, parallel-group study comparing the efficacy and safety of an oral artesunate-amodiaquine fixed-dose combination therapy over 3 subsequent days to an equivalent dose regimen of the individual drugs for the treatment of children with Plasmodium falciparum. http://www.controlled-trials.com/ISRCTN07576538
8. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 90 11103309
9. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. WR Taylor DJ Terlouw PL Olliaro NJ White P Brasseur FO ter Kuile, Bull World Health Organ 2006 84 956 964 10.2471/BLT.06.031492 17242831
10. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. A Brockman RE Paul TJ Anderson I Hackford L Phaiphun S Looareesuwan F Nosten KP Day, Am J Trop Med Hyg 1999 60 14 21 9988316
11. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). http://www.ich.org
12. Investigation of long-term stability of Amodiaquine and its metabolite Desethylamodiaquine in human plasma and in stock solution. Study 73082. PAREXEL, 2007
13. Evaluation of long-term stability of artesunate and its pharmacologically active metabolite dihydroartemisinine in human plasma samples. Study 87227. PAREXEL, 2007
14. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. SF Hietala A Bhattarai M Msellem D Roshammar AS Ali J Stromberg FW Hombhanje A Kaneko A Bjorkman M Ashton, J Pharmacokinet Pharmacodyn 2007 34 669 686 10.1007/s10928-007-9064-2 17620000
15. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. JA Simpson T Agbenyega KI Barnes G Di Perri P Folb M Gomes S Krishna S Krudsood S Looareesuwan S Mansor H McIlleron R Miller M Molyneux J Mwenechanya V Navaratnam F Nosten P Olliaro L Pang I Ribeiro M Tembo M van Vugt S Ward K Weerasuriya K Win NJ White, PLoS Med 2006 3 444 10.1371/journal.pmed.0030444 17132053
16. Interval estimation for the difference between independent proportions: comparison of eleven methods. RG Newcombe, Stat Med 1998 17 873 890 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM7793.0.CO;2-I 9595617
17. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. R Peto MC Pike P Armitage NE Breslow DR Cox SV Howard N Mantel K McPherson J Peto PG Smith, Br J Cancer 1977 35 1 39 831755
18. Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. DT Le Thi NH Le CH Nguyen D Phan Thi K Na-Bangchang, Drug Metab Pharmacokinet 2008 23 158 164 10.2133/dmpk.23.158 18574319
19. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. JS Sidhu M Ashton NV Huong TN Hai MO Karlsson ND Sy EN Jonsson LD Cong, Br J Clin Pharmacol 1998 45 347 354 10.1046/j.1365-2125.1998.t01-1-00686.x 9578181
20. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. FC Churchill LC Patchen CC Campbell IK Schwartz P Nguyen-Dinh CM Dickinson, Life Sci 1985 36 53 62 10.1016/0024- 3205(85)90285-1 3965841
21. The disposition of amodiaquine in Zambians and Nigerians with malaria. PA Winstanley O Simooya JM Kofi-Ekue O Walker LA Salako G Edwards ML Orme AM Breckenridge, Br J Clin Pharmacol 1990 29 695 701 2378788
22. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. FW Hombhanje I Hwaihwanje T Tsukahara J Saruwatari M Nakagawa H Osawa MM Paniu N Takahashi JK Lum B Aumora, et al. Br J Clin Pharmacol 2005 59 298 301 10.1111/j.1365-2125.2004.02257.x 15752375
23. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. P Newton Y Suputtamongkol P Teja-Isavadharm S Pukrittayakamee V Navaratnam I Bates N White, Antimicrob Agents Chemother 2000 44 972 977 10.1128/AAC.44.4.972-977.2000 10722499